uMRD: “the” endpoint or “an” endpoint for CLL?

Adam S. Kittai; Jennifer A. Woyach

doi:10.1182/blood.2022016927

uMRD: “the” endpoint or “an” endpoint for CLL?

Adam S. Kittai
, Jennifer A. Woyach

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	797-798
Number of pages	2
Journal	Blood
Volume	140
Issue number	8
DOIs	https://doi.org/10.1182/blood.2022016927
State	Published - Aug 25 2022

Access to Document

10.1182/blood.2022016927

Cite this

@article{053d40fa61484c79bd093ca9fda9df37,

title = "uMRD: “the” endpoint or “an” endpoint for CLL?",

author = "Kittai, \{Adam S.\} and Woyach, \{Jennifer A.\}",

note = "Funding Information: Conflict-of-interest disclosure: A.S.K. has consulted for Abbvie, Beigene, Bristol Myers Squibb, and Janssen. J.A.W. receives research funding from Pharmacyclics, Abbvie, Janssen, Karyopharm, Morphosys, and Schrodinger and has consulted for Abbvie, Pharmacyclics, Janssen, AstraZeneca, Beigene, Genentech, Loxo, and Newave. J.A.W. is a clinical scholar of the Leukemia and Lymphoma Society. Funding Information: Conflict-of-interest disclosure: A.S.K. has consulted for Abbvie, Beigene, Bristol Myers Squibb, and Janssen. J.A.W. receives research funding from Pharmacyclics, Abbvie, Janssen, Karyopharm, Morphosys, and Schrodinger and has consulted for Abbvie, Pharmacyclics, Janssen, AstraZeneca, Beigene, Genentech, Loxo, and Newave. J.A.W. is a clinical scholar of the Leukemia and Lymphoma Society. ",

year = "2022",

month = aug,

day = "25",

doi = "10.1182/blood.2022016927",

language = "English",

volume = "140",

pages = "797--798",

journal = "Blood",

issn = "0006-4971",

number = "8",

}

TY - JOUR

T1 - uMRD

T2 - “the” endpoint or “an” endpoint for CLL?

AU - Kittai, Adam S.

AU - Woyach, Jennifer A.

N1 - Funding Information: Conflict-of-interest disclosure: A.S.K. has consulted for Abbvie, Beigene, Bristol Myers Squibb, and Janssen. J.A.W. receives research funding from Pharmacyclics, Abbvie, Janssen, Karyopharm, Morphosys, and Schrodinger and has consulted for Abbvie, Pharmacyclics, Janssen, AstraZeneca, Beigene, Genentech, Loxo, and Newave. J.A.W. is a clinical scholar of the Leukemia and Lymphoma Society. Funding Information: Conflict-of-interest disclosure: A.S.K. has consulted for Abbvie, Beigene, Bristol Myers Squibb, and Janssen. J.A.W. receives research funding from Pharmacyclics, Abbvie, Janssen, Karyopharm, Morphosys, and Schrodinger and has consulted for Abbvie, Pharmacyclics, Janssen, AstraZeneca, Beigene, Genentech, Loxo, and Newave. J.A.W. is a clinical scholar of the Leukemia and Lymphoma Society.

PY - 2022/8/25

Y1 - 2022/8/25

UR - https://www.scopus.com/pages/publications/85136528068

U2 - 10.1182/blood.2022016927

DO - 10.1182/blood.2022016927

M3 - Editorial

C2 - 36006672

AN - SCOPUS:85136528068

SN - 0006-4971

VL - 140

SP - 797

EP - 798

JO - Blood

JF - Blood

IS - 8

ER -

uMRD: “the” endpoint or “an” endpoint for CLL?

Access to Document

Other files and links

Cite this